Why Does Medullary Thyroid Cancer Need Genetic Testing?

Genetic testing for medullary thyroid cancer looks for mutations in the RET gene, which are responsible for roughly a quarter of all MTC cases and decide whether the disease is hereditary. A positive result changes almost everything about how the disease gets managed, from the timing of surgery to how closely blood relatives need to be screened. Sporadic MTC, the remaining three-quarters of cases, doesn’t carry that inherited risk, but the tumor still needs the same genetic workup to rule it out. That one distinction decides whether a single patient is treated, or an entire family line gets tested.

According to Prof. Dr. Sandeep Nayak, a specialist in thyroid cancer treatment in India, “RET testing isn’t optional in MTC. It tells us whether we’re treating one patient or protecting an entire family.”

A RET mutation test does more than confirm a diagnosis, it maps out how the disease is likely to behave and who else might be carrying the same risk.

• RET Mutations: About one in four MTC cases trace back to an inherited mutation in the RET proto-oncogene, and finding it early reshapes the entire treatment plan before surgery even gets scheduled.
• MEN 2 Link: Hereditary MTC usually shows up as part of MEN 2A or MEN 2B syndrome, so a positive RET result typically triggers screening for other endocrine tumors too, not just the thyroid.
• Sporadic Cases: Sporadic MTC has no inherited cause, so testing here mainly rules out hereditary disease rather than predicting family risk. But that reassurance still matters.
• Family Risk: A confirmed mutation means first-degree relatives, including children, need their own RET test, and one blood draw can catch the disease decades before symptoms show up.

Which category a tumor falls into shapes every decision that follows, starting with how aggressively surgery gets approached. In RET-positive families, prophylactic thyroidectomy can prevent the cancer from developing at all.

Once a RET mutation is confirmed, the result feeds directly into decisions about surgery timing, monitoring frequency, and drug therapy.

• Surgery Timing: Children who test positive for high-risk RET mutations, particularly MEN 2B, may need a total thyroidectomy well before any tumor shows up on imaging, sometimes in infancy.
• Calcitonin Tracking: Genetic status also shapes how often calcitonin and CEA levels get checked after surgery, since hereditary cases carry a higher chance of recurrence over time.
• Drug Eligibility: Advanced or metastatic disease with a confirmed RET mutation may respond to targeted drugs that act directly on the mutated pathway rather than the tumor generally.
• Counseling Access: Genetic counseling helps families understand inheritance patterns and options, and honestly, this conversation matters just as much as the blood test itself.

None of these decisions happen in isolation. They all trace back to whether the RET test came back positive or negative. Families weighing this often ask is thyroid cancer hereditary, and the answer depends heavily on which type is involved.

Dr. Sandeep Nayak brings over two decades of surgical oncology experience to MTC cases, including RET-positive patients who need surgery planned around genetic risk rather than tumor size alone. His RABIT technique allows total thyroidectomy to be performed with no visible neck scar, which matters considerably for children undergoing prophylactic surgery.

Patients with hereditary MTC are tracked with calcitonin and CEA testing on a schedule built around their specific mutation, not a generic protocol. That kind of follow-up catches recurrence months, sometimes years, before it would otherwise turn up on a scan.